Lenti-HPV-07
HPV-induced cancers (cervical, oropharyngeal)
Phase I/IIaActive
Key Facts
Indication
HPV-induced cancers (cervical, oropharyngeal)
Phase
Phase I/IIa
Status
Active
Company
About Theravectys
TheraVectys is a clinical-stage biotech pioneering a lentiviral vector-based vaccine platform designed to induce potent and durable T cell immunity. Its lead program, Lenti-HPV-07, is a therapeutic vaccine for HPV-induced cancers currently in Phase I/IIa trials, with a pipeline spanning oncology and infectious diseases. The company holds an exclusive worldwide license from Institut Pasteur for its core technology and has demonstrated compelling preclinical efficacy, including 100% tumor eradication in HPV models and complete protection against SIV in non-human primates.
View full company profile